Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare - Takeaways - MDSpire

Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare

  • By

  • David D. Kim

  • Jennifer H. Hwang

  • A. Mark Fendrick

  • Dariush Mozaffarian

  • May 15, 2026

  • 0 min

Share

  • 1

    The MFN policy will reduce GLP-1RA prices but may lead to increased Medicare spending due to expanded obesity treatment coverage.

  • 2

    An estimated 30 million Medicare beneficiaries qualify for GLP-1RAs based on obesity treatment criteria.

  • 3

    Projected Medicare spending on GLP-1RAs for obesity treatment is $73.9 billion over 10 years, with $56.3 billion in estimated health care savings.

  • 4

    Cost neutrality for Medicare could be achieved at lower prices, such as $150 per month, with higher adherence rates impacting net spending.

  • 5

    Policy uncertainty surrounds the MFN pricing implementation and its potential interaction with the Inflation Reduction Act.

Original Source(s)

Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare

  • by David D. Kim, Jennifer H. Hwang, A. Mark Fendrick, Dariush Mozaffarian

  • May 15, 2026

Related Content

Pasteurized Akkermansia muciniphila alleviates high-fat diet-induced bone loss via Nr4a1-dependent Treg differentiation

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Adipokine profiles and genetic variants of leptin receptor, adiponectin, and ghrelin pathways in obesity: prospective 12-month outcomes after bariatric interventions